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Abstract
Many options exist for the treatment of localized prostate cancer. In the decision to
choose a therapeutic option for localized disease, many variables need to be considered such as
tumor characteristics, clinical stage, the patient’s overall health and life expectancy, and
preferences of both the physician and patient. Another important consideration is the healthrelated quality of life (HRQOL) implications of a given treatment option. The importance of
HRQOL relative to the potential side effects of prostate cancer treatments has grown over the
past few years. Although our collective awareness has increased, objective data on HRQOL for
prostate cancer treatment are lacking due to a paucity of prospective clinical trial data. This
review defines the concept of HRQOL, discusses what is currently known about the impact of
various treatments on HRQOL, and summarizes the recent literature in this area relating to the
management of localized prostate cancer.

Keywords: prostate cancer, radical prostatectomy, external beam radiation therapy,
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Introduction
Prostate-specific antigen (PSA)-based screening for prostate cancer (CaP) has resulted in
a stage migration, leading patients to be diagnosed earlier in the disease process, at a younger age
and with lower risk factors [1, 2]. Data from the large Cancer of the Prostate Strategic Urologic
Research Endeavor (CaPSURE) database demonstrated a significant increase in the proportion of
patients with low-risk tumor characteristics from 29.8% in 1989–1992 to 45.3% in 1999–2001
[2]. More importantly, the robust favorable long-term survival in low-risk CaP has become even
more pronounced in recent years because PSA testing has led to cancer diagnosis at an earlier
point of the disease course and to be alive longer with their disease. In fact, progression-free
survival following local intervention for low-risk CaP approaches 95% at 10 years [3].
Various established treatment options exist for clinically localized CaP, such as active
surveillance (AS), radical prostatectomy (RP), radiotherapy (RT), and brachytherapy (BT). Some
of these, such as radiation therapy, can include hormonal therapy in the regimen. Unfortunately,
there have been no adequately sized randomized clinical trials to directly compare the various
interventions for CaP, and past attempts to compare interventions such as brachytherapy and
radical prostatectomy have not been successful. Therefore, in the setting in which one treatment
option cannot be ruled superior to another, the side effect profiles of the different treatment
options are often considered with making a treatment decision. Understanding the health related
quality of life (HRQOL) enables the urologist and individual patient to have realistic
expectations and to optimize treatment decisions for the CaP patient. Customizing risk profile to
each patient can also prove to be important, such as taking into consideration the patient’s
baseline health, anxiety, and expectations. For example, a patient who has a history of

obstructive urinary symptoms related to symptomatic benign prostatic hyperplasia (BPH) may
benefit from surgical treatment of his cancer, which would also alleviate his symptoms of BPH.
A summary of common interventions for CaP and associated HRQOL side effects is
listed in Table 1. Because there is limited evidence that any of the treatments for localized
disease is superior to another in terms of overall survival, patients must consider other variables
when choosing therapy. One of these other considerations is quality of life (QOL). Recognition
of the importance of HRQOL related to the side effects of CaP treatments has grown over the
years. Although the awareness by physicians and patients has increased, there is still a paucity of
objective data of HRQOL for CaP treatment, primarily due to the relative lack of prospective
trials. It is critically important that clinicians understand the impact of CaP and its effect on
HRQOL so that they can better counsel their patients and make early interventions that improve
patient outcomes. The aim of this review is to briefly establish the definition of HRQOL as well
as the known consequences of CaP treatments on HRQOL, and review updates on this topic in
recent literature concerning the management of localized CaP.

Definition and Measurement of HRQOL in CaP
HRQOL is measured using standardized questionnaires, which collect patient-centric data
and provide an objective assessment and perception of both generic and disease specific
domains. In the past, health care providers would document what was perceived QOL, but a
more accurate measure includes patient-driven perception of personal health, the ability to
function in life, and overall sense of satisfaction with life experiences [4]. The ultimate goal of
HRQOL is to detect variation in the natural history of disease and treatment effects not described
by vital status or observations recorded in the clinical record [5]. There are several validated

questionnaires, also commonly described as “instruments” or “tools,” developed for patients with
CaP.
The University of California Los Angeles Prostate Cancer Index (UCLA-PCI) was the
first validated questionnaire specifically designed to measure HRQOL in localized CaP patients.
General HRQOL domains were borrowed from the established Medical Outcomes Study Short
Form (SF-36), and prostate-specific domains were included: urinary function and bother, sexual
function and bother, and bowel function and bother. Briefly, the SF-36, which is perhaps the
most widely used tool for general HRQOL, consists of eight scaled scores: vitality, physical
functioning, bodily pain, general health perceptions, physical role functioning, emotional role
functioning, social role functioning, and mental health [5].
The Expanded Prostate Cancer Index Composite (EPIC) is a comprehensive instrument
designed to evaluate patient function and bother after CaP treatment. Content from the original
UCLA-PCI was expanded with guidance from a cohort of localized CaP patients and an expert
panel comprised of urologic oncologists, radiation oncologists, survey researchers, and CaP
nurses. This extensive panel found a need to augment the UCLA-PCI with items to capture
additional concerns relevant to BT, RT, RP, and androgen deprivation. Symptom-specific bother
items corresponding to each symptom item were added to elicit multi-item bother scales for each
HRQOL domain [4].
The European Organization for Research and Treatment of Cancer Core Quality of Life
Questionnaire (EORTC QLQ-C30) is a 30-item self-reported questionnaire developed to assess
the QOL of cancer patients. It is grouped into five functional subscales: role, physical, cognitive,
emotional, and social functioning. In addition, there are three multi-item symptom scales
(fatigue, pain, and nausea and vomiting), individual questions concerning common symptoms in

cancer patients, and two questions assessing overall QOL. The EORTC QLQPR25 was
developed to incorporate an additional 25-item subset specific to CaP [6].

Effect of Patient Treatment Options on Patient QOL
Active Surveillance
CaP can progress slowly and, with or without treatment, a large number of men can live
many years after diagnosis. The realization that low-risk CaP may sometimes be overtreated by
surgery or radiation has been an impetus in the development of an active surveillance (AS)
protocol. Therefore, men with favorable disease-specific features are candidates for AS, and
perhaps can benefit from the avoidance of various side effects of treatment of localized
CaP such as incontinence, bleeding, gastrointestinal toxicity, and erectile dysfunction. Although
physical side effects may be avoided with AS, there is an emerging concern that patients may be
at an increased risk of psychologic distress. HRQOL was evaluated in 129 men that were
enrolled in the Prostate Cancer Research International: Active Surveillance (PRIAS) study.
Although for the most part, AS was well tolerated among the cohort, certain risk factors for
patients who may not do well on AS emerged. A perception of the physician contributing to the
majority of the decision making, a poor physical health score, a high neuroticism (anxiety) score,
and a high PSA value all had significant positive associations with lower HRQOL scores [7].
Burnet et al. [8] also noted that AS, as a treatment entity, did not offer higher overall
psychological distress compared with other CaP treatments, but analyses indicated that higher
anxiety scores were significantly associated with younger age and a longer time interval from
diagnosis. In addition, higher depression scores were significantly associated with a longer
interval since diagnosis (P<0.05), but not with management by AS. Therefore, although AS has

substantial benefits, it can also have significant effects on QOL, and additional research is
needed to define how to minimize the specific QOL domains affected.
The National Cancer Institute (NCI)-endorsed phase III Study of Active Surveillance
Therapy Against Radical Treatment in Patients Diagnosed With Favorable-Risk Prostate Cancer
(START) trial, currently enrolling patients in the United States and Canada, will compare the
disease-specific survival of patients who have favorable risk CaP treated with RP or radical RT
at the initial diagnosis with that of patients whose treatment is AS and selective active treatment
intervention (either radiation or surgery). In addition to cancer-related outcomes, the study will
use a number of QOL instruments to further examine the QOL problems these different
approaches may involve [9].

Radical Prostatectomy
Several trials have shown that RP has significant negative effect on multiple QOL
domains such as lower sexual function score, lower urinary function and incontinence scores,
and lower physical HRQOL [10, 11••, 12], [13••]. Although certain advances have been made
that help diminish these side effects, such as nerve sparing prostatectomy (NSP) or roboticassisted radical prostatectomy (RARP), their impact on HRQOL still remains controversial.
Significant controversy exists regarding the outcomes of RARP and open RP. Although
there are limited published data on HRQOL outcomes specifically to RARP, one can look at
functional outcomes and deduce the effects on QOL from the open RRP patients. Coelho et al.
[14] concluded, after evaluating current RARP outcomes, that this technique offers comparable
functional outcomes to open RRP. Therefore, RARP should theoretically offer similar HRQOL
scores to open RRP. These outcomes are different than those reported in a recent article by Hu et
al. [15•], which examined minimally invasive RP (all laparoscopic techniques) and traditional

open RP. Measured outcomes of incontinence and erectile dysfunction were higher in the
minimally invasive group compared with the open RP group, using a dataset of nearly 2000
Medicare patients from the years 2003 to 2007. Among the criticism of the report, the study
failed to stratify the patients between RARP and laparoscopic RP, for which a more pronounced
learning curve exists. In addition, the time period (2003– 2007) that was examined was when
minimally invasive prostatectomy was first becoming popular and more widely available in
United States, putatively during most surgeons’ initial learning curve. Finally, the study did not
control hospital and surgeon case volumes, which is known to correlate with outcomes.
Nevertheless, the data suggested worse functional outcomes in patients undergoing minimally
invasive RP when compared with open RP.
Preserving the neurovascular bundles (NSP) reduces the incidence of impotence post
prostatectomy in both open RP and robotic-assisted RP [11••, 16]. In addition, some studies have
also suggested that NSP can help improve urinary function. Abel et al. [16] evaluated 91
consecutive patients divided into two cohorts according to the percentage of nerve sparing
performed, >50% versus ≤50%, at the time of RP. Nerve sparing was associated with better
urinary function (P=0.014) and urinary bother (P=0.043). After adjusting for preoperative
variables, the increased NSP group scored 8.4 points higher for urinary function and 8.5 points
higher for urinary bother compared with the non- NSP group. Long-term (>5 years)
improvement in urinary incontinence was seen in the NSP group by Nandipati et al. [17].
Urinary continence status was defined as completely pad-free or wearing a single pad for
protection (dry pad). Overall incontinence rate was reported to be higher in the non-NS than the
bilateral NS (29.5% vs 9.1%, respectively; P<0.05). Return of incontinence was also
significantly quicker in the bilateral NS group. Although several anecdotal opinions exist, such

as a more meticulous apical dissection at the time of NSP and more careful overall technique, the
exact causal mechanism of NSP in improving urinary function is not known.

Radiotherapy of the Prostate
Patients undergoing RT for localized CaP can have urinary, sexual, and gastrointestinal
tract dysfunction after treatment. However, the symptomatology of urinary dysfunction after RT
is different than that of patients who undergo surgery. Unlike surgery, which can result in stress
urinary incontinence, RT can result in irritative voiding symptoms, such as urgency, frequency,
and urge incontinence, that negatively affect overall urinary function and HRQOL. Also, specific
to RT is a higher incidence bowel irritation. BT and RT were both associated with a reduced
QOL related to bowel function early after treatment, continuing in some patients for more than a
year. Sanda et al. [11••] reported rectal urgency, frequency, pain, fecal incontinence, or
hematochezia-caused distress related to bowel function in 9% of patients a year after RT. The
most predominant severe acute toxicity after BT is urinary retention requiring catheterization
[18]. In fact, Roeloffzen et al. [18] reported that acute urinary retention after prostate BT has a
significant negative impact on patients’ HRQOL up to 6 years after treatment, in terms of both
global QOL measures and urinary symptom scores. Proper selection of patients can minimize the
risk of retention following BT.
Postoperative RT for CaP in a salvage or an adjuvant setting presents a unique challenge,
in that maximizing urinary continence and potency prior to delivery of RT is of concern.
Pinkawa et al. [19] evaluated 101 patients prospectively that received RT for positive surgical
margins and/or persisting or rising PSA levels after RP. Median time between RP and beginning
of RT was 16 months. Function and bother scores at baseline and different time intervals were

recorded after RT. The time between RP and RT did not correlate with a significant difference in
function scores. RT-associated sexual toxicity played a minor role in this study because only 7%
of patients reported erections firm enough for intercourse. HRQOL scores in the urinary and
bowel domains decreased significantly in the acute phase. Urinary scores recovered rapidly
within the first weeks after RT. On the other hand, bowel scores remained significantly lower for
a longer period of time, and only recovered back to baseline 1 year after RT. Twenty-nine
patients received a course of androgen deprivation for a median duration of 9 months prior to
RT. HRQOL scores in this subgroup decreased in the hormonal domain but returned back to
baseline 1 year after RT.
Androgen deprivation therapy is well known to have a significant impact on hormonal
HRQOL domain. Symptoms in this category include hot flashes, gynecomastia, lack of energy,
weight gain, bone loss, increased risk of metabolic syndrome, and depressive mood changes.
These concerns are increasingly relevant in the measurement of consequences from localized
CaP treatment because the use of neoadjuvant and adjuvant hormonal therapy has become more
common with RT. Neoadjuvant hormonal therapy can also be used for cytoreduction for patients
with large prostates, to make them eligible for BT or surgical intervention. Side effects of
androgen deprivation in localized disease must be discussed with patients, as their administration
can have a significant and long-lasting impact on the QOL of patients.

Physician Awareness of HRQOL
Increased awareness of the impact of cancer on HRQOL of patients and accurate study of
HRQOL have been slow to permeate the field of urologic oncology. A study by Sonn et al. [20•]
examined the frequency of various impairment factors, such fatigue, pain, and sexual, urinary,

and bowel dysfunction who had undergone RP, BT, or External beam radiation therapy recorded
by the physician and those self-reported by the patient. The authors compared a modern cohort of
a period from 2000 to 2007 with that from 1995 to 2000. Participants independently completed
the SF-36 and the UCLA-PCI. Urologists noted impairment in urinary and sexual function more
accurately than fatigue or pain. Disagreement between physician and participant ratings did not
vary dramatically from short-term to long-term follow-up, or from the earlier to the later cohort,
indicating, despite the increased awareness in literature, a need for further provider awareness on
QOL issues. As the time from primary treatment increased, patients did report less impairment in
all domains, but physicians recorded more improvement than did their patients. This study
clearly shows that the wide gap continues to exist between the HRQOL that patients report and
that which their physicians assess.

Impact of Screening and Diagnosis on HRQOL
PSA screening and monitoring can adversely affect patients’ anxiety levels and therefore
have a diminutive effect on their QOL. Even prior to being diagnosed with CaP, there can be
mental anguish and anxiety resulting in a decreased QOL from CaP screening. Carlsson et al.
[21] evaluated the anxiety levels of nearly 1800 men with PSA ≥3 ng/mL partaking in the
European Randomized Study of Screening for Prostate Cancer. The study illustrated that most
men have low to moderate anxiety while waiting for further clinical examination for an elevated
PSA, and that <5% of men reported high levels of anxiety. Despite the high sensitivity of PSA,
variable factors can falsely elevate PSA, including benign enlargement of the prostate. Katz et al.
[22] evaluated the effect on psychological well-being of 109 men with an abnormal PSA test or
an abnormal digital rectal examination (DRE) but a negative biopsy result. Men with abnormal

CaP screening tests report increased cancer related worry and more problems with sexual
function, despite having a negative biopsy result. Therefore, false positive results may contribute
to a significant decrease in QOL, stressing the point that effective counseling is recommended
before CaP screening and during follow-up.
Increased anxiety is common after being diagnosed with CaP. Understanding the specific
domains of well-being affected by the diagnosis can help urologists mediate the negative effects
[5]. Love et al. [23] conducted a prospective QOL evaluation of 367 men newly diagnosed with
either early or advanced CaP compared with a CaP-free, age-matched comparison group of men.
The diagnosis of CaP had a significant, negative effect on vitality, social functioning, role
emotional, and mental status, as measured by the SF-36. Additionally, a greater rate of anxiety
was seen in men diagnosed with early-stage (5.2%) and advanced-stage (5.8%) CaP compared
with aged-matched controls. Strategies that may introduce early recognition and intervention
may perhaps slow the deterioration or even improve the patient’s QOL, while the patient is going
through a treatment process. The elderly population in the United States is no exception. A
longitudinal population based study by Reeve et al. [24] examined the impact a diagnosis of CaP
has on HRQOL in the aging population. Patients that were newly diagnosed with prostate cancer
experienced statistical declines in physical health (mean score decline of 3.4) and significant
decreases in mental health (mean score decline of 2.8) relative to the mean change of the control
subjects.
This also illustrates the importance for urologists to understand the impact of CaP and its
treatment on QOL so that patients can be better counseled on expectations and that care
providers can provide early interventions for certain QOL domains.

Preoperative Tumor Characteristics Effect on HRQOL
Are there certain tumor parameters that help predict which patients with CaP will do
better than their counterparts? Gacci et al. [25] retrospectively reviewed 595 patients who had
undergone either RP or RT. Significantly better urinary function and bother scores were noted in
patients with localized, low-risk CaP (cT1-2, Gleason score ≤3 + 3, and PSA ≤10 ng/mL).
Moreover, men with low clinical stage, low Gleason score, and low preoperative PSA had
significantly better sexual function scores. Interestingly, there was not a statistical difference in
sexual bother scores in the higher risk patients, perhaps reflecting better preoperative counseling
and posttreatment expectations of sexual recovery. Moreover, biochemical recurrence also
influenced urinary function and bother, as well as sexual function and bother, perhaps reflective
of a general decrease in QOL after discovery of cancer recurrence.

HRQOL and Survival
It has been shown that a higher HRQOL, after controlling from clinical and demographic
variables, can improve survival in several types of malignancies, including breast cancer [26].
Aside from a better QOL, is there a similar impact in survival in patients diagnosed with CaP by
merely improving QOL? Sadetsky et al. [27] examined this issue in a recent article, in which
they evaluated patients from the CaPSURE database. HRQOL and survival in patients with CaP
were evaluated after controlling for age at diagnosis, type of treatment received, clinical risk
classification, and number of comorbidities. Higher levels of physical function and general
health were significantly associated with better survival (HR, 0.49; 95% CI, 0.32– 0.78, and HR
0.51, 95% CI, 0.35–0.75, respectively). It is not clear if there is a direct causal relationship
between HRQOL and survival from CaP, but perhaps this association could provide the stimulus

to investigate and provide a link between a patient’s perception and the severity of the
underlying disease.

Spousal Effect on HQROL
Patients with CaP often rely exclusively on their spouses for support, and therefore, the
role as a primary caregiver can be stressful for spouses. Despite the high prevalence of prostate
cancer, little information is available on the QOL of men and their spouses during the phases of
diagnosis and treatment of CaP. Northouse et al. [28] evaluated patients with CaP and their
spouses through a comprehensive psychosocial assessment across three phases of illness: new
diagnosis, biochemical recurrence, and advanced CaP. Spouses’ risk for distress scores did not
differ from patients’ scores, indicating that spouses are not immune to the effects of illness. In
fact, spouses had a greater need for the intervention than patients.
Decreases in the QOL from CaP treatment can extend to a patient’s spouse or partner.
This was shown by Sanda et al. [11••], in which significant distress in the spouse was reported 1
year after initial treatment. As one would expect, the spousal group with the highest erectile
dysfunction related distress was reported by 44% of partners in the RP group, 22% in the RT
group, and only 13% in the BT group. Obviously, it must be noted that the RP patient group had
higher baseline sexual scores and experienced the greatest decrease in QOL score, which is
reflected in the spouse group. In addition, the RP group was younger and with less comorbidities
and perhaps enjoying a more meaningful sexual life, which is precipitously affected immediately
after surgery. Patients’ reported bowel and urinary symptoms associated with spousal distress
were lower and ranged from 3% to 7% in all three groups. Finally, the level of spousal distress
arising from a patient’s sexual and urinary symptoms after primary CaP treatment was also

associated with the partner’s level of satisfaction with the treatment outcome in multivariate
analysis.
Clearly, a health care provider should also include the patient’s partner when deciding the
appropriate intervention for CaP. Similar to other studies, Badr and Taylor [29] reported that
within couples, patients’ and their partners’ sexual function and satisfaction were very similar.
When patients had poor erectile function, their partners were more likely to report that the couple
avoided open spousal discussions; this in turn was associated with partners’ marital distress.
Patients and partners who reported high levels of mutual constructive communication also
reported greater marital adjustment, regardless of their own sexual satisfaction. The authors of
the study concluded that psychosocial interventions that facilitate healthy spousal
communication and address the sexual rehabilitation needs of patients and their partners after
CaP treatment is important.
Several studies have demonstrated that early intervention by the health care provider can
improve QOL. Although no difference was seen between patient groups on prostate specific
symptoms, spouses in the intervention group reported higher QOL, more self-efficacy, better
communication, and less negative appraisal of caregiving, uncertainty, hopelessness, and
symptom distress lasting up to 12 months compared with controls [30].
Harden et al. [31] applied the Family Involvement, Optimistic Outlook, Coping
Effectiveness, Uncertainty Reduction, and Symptom Management (FOCUS) program, which
was originally developed for women with advanced breast cancer and their family caregivers, to
prostate cancer patients and partners. Couples identified this as an opportunity to raise difficult
issues they might not have discussed with their care provider, and reported high satisfaction with
the program. Spouse participation in a supportive, educative intervention increased

communication with their husbands, lessened their uncertainty, and reduced their negative
appraisal of caregiving. Unique to CaP patients is that the vast majority of partners are women
(99% in this study). Partners in this study reported more satisfaction overall than caregivers of
breast cancer patients (64% were husbands). These differences may be related to the more active
caregiving or illness management role that female spouses versus the supportive role caregivers
(primarily husbands) of breast cancer patients assume.

HRQOL in Minority Populations
Controlling for variables, does the black population experience similar QOL compared
with the white population undergoing CaP treatment? Jayadevappa et al. [32] conducted a
prospective study evaluating QOL and satisfaction with care after RP or RT. Compared with
white patients, black patients were less likely to choose RP as primary treatment, although when
statistically controlled, ethnicity was not associated with treatment type in statistical significance.
Baseline prostate QOL scores were similar in both groups, except the black group reported
higher pains in back, legs, or hips. There were a higher percentage of black men accrued from
the Veterans Administration (68% vs 42%). It is unclear that this difference serves as a
discrepancy in the consistency of are delivered between the two groups. The majority of white
men were college educated, married, and had an annual income of >$40,000 (63% vs 22% in the
black population). Outcomes of this study included the following: black men took a longer time
to return to their baseline generic and sexual bother HRQOL scores; and black men reported
poorer outcomes by 12 months for some generic and prostate-specific HRQOL domains,
including lower 12- month scores on role physical, role emotional, bodily pain, urinary function,
and urinary bother. The etiologies of these discrepancies are unknown, but perhaps it is because

black patients express lower physician trust than their white counterparts [33]. Alternatively,
black patients may have lower satisfaction rates with the services they receive. Regardless, this
highlights the need for further research to help health care providers to be effective in improving
and reducing variations in outcomes seen in the racial minority population.

Conclusions
One of the most useful papers on HRQOL in CaP was published by Sanda and associates
[11••]. This prospective study of more than 1,200 patients and 625 spouses or partners serves as
a landmark paper in the field and should be standard reading for any provider who counsels
patients with localized prostate cancer.
QOL is affected in both the short- and long-term for men treated for CaP. QOL issues are
important for treating physicians to be familiar with and understand as we strive to provide
optimum care to these men and their families along the often lengthy period of the disease
trajectory. A considerable impact on the QOL of patients’ families is associated with definitive
treatment. The mere diagnosis of CaP and AS strategies can also negatively affect patients’
QOL. Therefore, the patient, spouse or partner, and physician all need to carefully consider, not
only the efficacy, but also the consequences of each treatment option, including the potential
adverse effects and effect on QOL. Investigations of all new and existing therapies should
attempt to gather prospective and objective data on HRQOL.
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Treatment Modality

HRQOL Side Effects

AS

Greater level of depression [8]
Higher anxiety score [7]
Greater level of depression [33]
Lower sexual function score [10,11••,12]
Lower urinary function score [10,11••,12]
Lower urinary incontinence score, but improved urinary
irritation or obstruction symptoms [11••]
Greater level of depression [33]
Lower sexual function score, worsened with ADT [11••]
Lower bowel function score [11••]
Lower physical HR-QOL, worsened with ADT [11••]
Greater level of depression [33]
Lower urinary irritation or obstruction scores [11••,17]
Lower bowel function score [11••]

RP

EBRT

BT

